Long Term Safety of Immediate-release Tolvaptan in Subjects With Autosomal Dominant Polycystic Kidney Disease
Status:
Completed
Trial end date:
2018-11-09
Target enrollment:
Participant gender:
Summary
The purpose of the trial was to evaluate and describe the long term safety of tolvaptan in
participants with autosomal dominant polycystic kidney disease (ADPKD).
Phase:
Phase 3
Details
Lead Sponsor:
Otsuka Pharmaceutical Development & Commercialization, Inc.